References
Al-Maghrebi M, Kehinde EO, Anim JT, Sheikh M (2012) The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer. Int Urol Nephrol 44:1681–1689
Langner C, Rupar G, Leibl S et al (2006) Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch 448:325–330
Guzman G, Wu SJ, Kajdacsy-Balla A, Cotler SJ (2006) Alpha-methylacyl-CoA racemase (AMACR/P504S) can distinguish hepatocellular carcinoma and dysplastic hepatocytes from benign nondysplastic hepatocytes. Appl Immunohistochem Mol Morphol 14:411–416
Mroz A, Kiedrowski M, Lewandowski Z (2012) Alpha-methylacyl-CoA racemase (AMACR) in gastric cancer: correlation with clinicopathologic data and disease-free survival. Appl Immunohistochem Mol Morphol (in press)
Marx A, Simon P, Simon R et al (2008) AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch 453:243–248
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kapoor, S. AMACR: an emerging diagnostic and prognostic tool in systemic malignancies. Int Urol Nephrol 45, 439–440 (2013). https://doi.org/10.1007/s11255-013-0393-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-013-0393-3